MYC activation is a hallmark of cancer initiation and maintenance

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 6, 2014, Pages

  Gabay, Meital ^a   Li, Yulin ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BREAST CARCINOMA; CARCINOGENESIS; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPLICATION; GENE MUTATION; HUMAN; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; NEOPLASM; NONHUMAN; ONCOGENE MYC; OSSIFICATION; OSTEOSARCOMA; PATHOGENESIS; T CELL LYMPHOMA; THYROID CANCER; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; TUMOR MICROENVIRONMENT;

CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84887147170     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014241     Document Type: Article

References (128)

1. Alitalo K, Bishop JM, Smith DH, Chen EY, Colby WW, Levinson AD. 1983. Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci 80: 100-104.
2. Arvanitis C, Felsher DW. 2005. Conditionally MYC: Insights from novel transgenic models. Cancer Lett 226: 95-99.
3. Bachireddy P, Rakhra K, Felsher DW. 2012. Immunology in the clinic review series; focus on cancer: Multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 167: 188-194.
4. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, et al. 2004. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2: e332.
5. Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW. 2008. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PloS ONE 3: e2493.
6. Bowden GT, Schneider B, Domann R, Kulesz-Martin M. 1994. Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. Cancer Res 54: 1882s-1885s.
7. Boxer LM, Dang CV. 2001. Translocations involving c-myc and c-myc function. Oncogene 20: 5595-5610.
8. Boxer RB, Jang JW, Sintasath L, Chodosh LA. 2004. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6: 577-586.
9. Calvisi DF, Thorgeirsson SS. 2005. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicologic Pathol 33: 181-184.
10. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. 2011. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 71: 286-2297.
11. Cavin LG, Wang F, Factor VM, Kaur S, Venkatraman M, Thorgeirsson SS, Arsura M. 2005. Transforming growth factor-a inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kB in murine hepatocellular carcinomas. Mol Cancer Res 3: 403-412.
12. Cermelli S, Jang IS, Bernard B, Grandori C. 2014. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4: a014209.
13. Cerni C, Mougneau E, Zerlin M, Julius M, Marcu KB, Cuzin F. 1986. c-myc and functionally related oncogenes induce both high rates of sister chromatid exchange and abnormal karyotypes in rat fibroblasts. Curr Top Microbiol Immunol 132: 193-201.
14. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, et al. 2011. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121: 4700-4711.
15. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O’Hagan R, Pantginis J, Zhou H, et al. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
16. Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. 2011. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci 108: 17432-17437.
17. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. 2011. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PloS ONE 6: e17449.
18. Compere SJ, Baldacci P, Sharpe AH, Thompson T, Land H, Jaenisch R. 1989. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Proc Natl Acad Sci 86: 2224-2228.
19. Conacci-Sorrell M, McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: a014357.
20. Dang CV. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11.
21. Dang CV. 2012. MYC on the path to cancer. Cell 149: 22-35.
22. Dang CV. 2013. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3: a014217.
23. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. 1999. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253: 63-77.
24. Dang CV, Le A, Gao P. 2009. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483.
25. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, et al. 2001. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239.
26. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
27. DeoCampo ND, Wilson MR, Trosko JE. 2000. Cooperation of bcl-2 and myc in the neoplastic transformation of normal rat liver epithelial cells is related to the down-regulation of gap junction-mediated intercellular communication. Carcinogenesis 21: 1501-1506.
28. Dias N, Stein CA. 2002. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 1: 347-355.
29. Dominguez-Sola D, Gautier J. 2014. MYC and the control of DNA replication. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014423.
30. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R. 2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
31. Eilers M, Eisenman RN. 2008. Myc’s broad reach. Genes Dev 22: 2755-2766.
32. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R. 1986. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci 83: 4834-4838.
33. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
34. Felsher DW. 2003. Cancer revoked: Oncogenes as therapeutic targets. Nat Rev Cancer 3: 375-380.
35. Felsher DW. 2006. Tumor dormancy: Death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 5: 1808-1811.
36. Felsher DW. 2008. Oncogene addiction versus oncogene amnesia: Perhaps more than just a bad habit? Cancer Res 68: 3081-3086.
37. Felsher DW, Bishop JM. 1999a. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
38. Felsher DW, Bishop JM. 1999b. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci 96: 3940-3944.
39. Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM. 2000. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci 97: 10544-10548.
40. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
41. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
42. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, et al. 1998. C-myc and c-fos in human osteosarcoma: Prognostic value of mRNA and protein expression. Oncology 55: 556-563.
43. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
44. Gibson AW, Cheng T, Johnston RN. 1995. Apoptosis induced by c-myc overexpression is dependent on growth conditions. Exp Cell Res 218: 351-358.
45. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. 2004. Conditional animal models: A strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 14: 3-11.
46. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegue E, Tang F, et al. 2006. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci 103: 16266-16271.
47. Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, et al. 2003. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 17: 1569-1574.
48. Green DR. 1997. A Myc-induced apoptosis pathway surfaces. Science 278: 1246-1247.
49. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140: 883-899.
50. Hermeking H. 2003. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 3: 163-175.
51. Hoffman B, Liebermann DA. 2008. Apoptotic signaling by c-MYC. Oncogene 27: 6462-6472.
52. Huettner CS, Zhang P, Van Etten RA, Tenen DG. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57-60.
53. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13: 2678-2690.
54. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104.
55. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, et al. 2007. Mutations in BRAF and KRAS converge on activation of the mitogenactivated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939.
56. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. 1999. Drosophila myc regulates cellular growth during development. Cell 98: 779-790.
57. Jonkers J, Berns A. 1996. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1287: 29-57.
58. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. 2003a. Defective double-strand DNA break repairand chromosomal translocations by MYC overexpression. Proc Natl Acad Sci 100: 9974-9979.
59. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. 2003b. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101: 2797-2803.
60. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y. 1999. Amplification of c-myc in hepatocellular carcinoma: Correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57: 157-163.
61. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al. 2012. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353.
62. Kool J, Berns A. 2009. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer 9: 389-399.
63. Kuzyk A, Mai S. 2014. c-MYC induced genomic instability. Cold Spring Harb Perspect Med 4: a014373.
64. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. 1993. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2: 163-167.
65. Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI. 2006. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res 66: 4591-4601.
66. Levens D. 2013. Cellular MYCRo economics: Balancing MYC function with MYC expression. Cold Spring Harb Perspect Med 3: a014233.
67. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, et al. 2007. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81-93.
68. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
69. Lowe SW, Cepero E, Evan G. 2004. Intrinsic tumour suppression. Nature 432: 307-315.
70. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136: 823-837.
71. Mai S, Hanley-Hyde J, Fluri M. 1996. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12: 277-288.
72. Makino R, Hayashi K, Sugimura T. 1984. C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment. Nature 310: 697-698.
73. Maksimenko A, Malvy C. 2005. Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets 9: 825-830.
74. Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T. 2004. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer J 110: 336-342.
75. McKeown MR, Bradner JE. 2014. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014266.
76. Mendrysa SM, Akagi K, Roayaei J, Lien WH, Copeland NG, Jenkins NA, Eisenman RN. 2010. An integrated geneticgenomic approach for the identification of novel cancer loci in mice sensitized to c-Myc-induced apoptosis. Genes Cancer 1: 465-479.
77. Mikkers H, Berns A. 2003. Retroviral insertional mutagenesis: Tagging cancer pathways. Adv Cancer Res 88: 53-99.
78. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A. 2002. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32: 153-159.
79. Morrish F, Hockenbery D. 2014. MYC and mitochondrial biogenesis. Cold Spring Harb Perspect Med 4: a014225.
80. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14: 447-457.
81. Murray MJ, Cunningham JM, Parada LF, Dautry F, Lebowitz P, Weinberg RA. 1983. The HL-60 transforming sequence: A ras oncogene coexisting with altered myc genes in hematopoietic tumors. Cell 33: 749-757.
82. Neto-Silva RM, de Beco S, Johnston LA. 2010. Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell 19: 507-520.
83. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
84. Nilsson JA, Cleveland JL. 2003. Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021.
85. O’Shea JM, Ayer DE. 2013. Coordination of nutrient availability and utilization by MAX-and MLX-centered transcription networks. Cold Spring Harb Perspect Med 3: a014258.
86. Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M. 2004. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: Therapeutic implications. Ann N Y Acad Sci 1028: 90-103.
87. Pelengaris S, Khan M, Evan GI. 2002. Suppression of Mycinduced apoptosis in b cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
88. Rahl PB, Young RA. 2014. MYC and transcription elongation. Cold Spring Harb Perspect Med 4: a014340.
89. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, et al. 2010. CD4þ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18: 485-498.
90. Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW. 2006. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 66: 6598-6605.
91. Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H, Dorken B, Jenuwein T, Schmitt CA. 2010. Tumor stroma-derived TGF-b limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17: 262-272.
92. Restifo NP. 2010. Can antitumor immunity help to explain “oncogene addiction?” Cancer Cell 18: 403-405.
93. Rooney CM, Rowe M, Wallace LE, Rickinson AB. 1985. Epstein-Barr virus-positive Burkitt’s lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317: 629-631.
94. Ruggero D, Pandolfi PP. 2003. Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192.
95. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S. 2011. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PloS ONE 6: e22284.
96. Schmitt CA, Lowe SW. 2001. Bcl-2 mediates chemoresistance in matched pairs of primary Em-myc lymphomas in vivo. Blood Cells Mol Dis 27: 206-216.
97. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677.
98. Shachaf CM, Felsher DW. 2005. Tumor dormancy and MYC inactivation: Pushing cancer to the brink of normalcy. Cancer Res 65: 4471-4474.
99. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
100. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, et al. 2007. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110: 2674-2684.
101. Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, et al. 2008. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 68: 5132-5142.
102. Sharma SV, Settleman J. 2007. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
103. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. 2006. A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
104. Sheiness D, Fanshier L, Bishop JM. 1978. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol 28: 600-610.
105. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. 2011. Endogenous Myc maintains the tumor microenvironment. Genes Dev 25: 907-916.
106. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. 2007. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218.
107. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
108. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27: 504-513.
109. Spencer CA, Groudine M. 1991. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56: 1-48.
110. Srinivasan SV, Dominguez-Sola D, Wang LC, Hyrien O, Gautier J. 2013. Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Reps 3: 1629-1639.
111. Stein CA, Benimetskaya L, Mani S. 2005. Antisense strategies for oncogene inactivation. Semin Oncol 32: 563-572.
112. Stock C, Kager L, Fink FM, Gadner H, Ambros PF. 2000. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 28: 329-336.
113. Tamm I, Dorken B, Hartmann G. 2001. Antisense therapy in oncology: New hope for an old idea? Lancet 358: 489-497.
114. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, et al. 2012. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci 109: 9545-9550.
115. Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, et al. 2011. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 3: 103-199.
116. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
117. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Moroy T, Felsher DW, Eilers M. 2010a. The interaction between Myc and Miz1 is required to antagonize TGFb-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 24: 1281-1294.
118. van Riggelen J, Yetil A, Felsher DW. 2010b. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10: 301-309.
119. Verdine GL, Walensky LD. 2007. The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264-7270.
120. Vita M, Henriksson M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330.
121. Weinstein IB. 2002. Cancer. Addiction to oncogenes—The Achilles heal of cancer. Science 297: 63-64.
122. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res 68: 3077-3080.
123. Welm AL, Kim S, Welm BE, Bishop JM. 2005. METand MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci 102: 4324-4329.
124. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci 105: 18782-18787.
125. Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. 2008. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet 4: e1000090.
126. Yan C, Higgins PJ. 2013. Drugging the undruggable: Transcription therapy for cancer. Biochim Biophys Acta 1835: 76-85.
127. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. 2010. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci 107: 13836-13841.
128. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.